- Home
- XNCR
XNCR
Xencor Inc.
as 09-12-2025 11:35am EST
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 547.8M | IPO Year: | 2013 |
| Target Price: | $23.33 | AVG Volume (30 days): | 726.1K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.92 - $27.24 | Next Earning Date: | 11-05-2025 |
| Revenue: | $146,929,000 | Revenue Growth: | -2.07% |
| Revenue Growth (this year): | 22.06% | Revenue Growth (next year): | -1.99% |
Latest Xencor Inc. News
XNCR Breaking Stock News: Dive into XNCR Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
RBC Cuts Xencor (XNCR) Price Target but Keeps Outperform Rating
Argus Research
2 months ago
XNCR: Raising target price to $7.00
Argus Research
3 months ago
XNCR: Rating decreased to a SELL
Argus Research
3 months ago
XNCR: What does Argus have to say about XNCR?
Argus Research
4 months ago
XNCR: What does Argus have to say about XNCR?
Argus Research
4 months ago
XNCR: What does Argus have to say about XNCR?
Zacks
4 months ago
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Associated Press Finance
4 months ago
Xencor: Q1 Earnings Snapshot
Compare XNCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XNCR Xencor Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.